Badi El Osta
- Department of Hematology and Medical Oncology
Associate Professor
- (404) 778-1900
- badi.elosta@emoryhealthcare.org
Academic Appointment
- Associate Professor, Department of Hematology and Medical Oncology, Emory University School of Medicine
Education
Degrees
- MD from Saint Joseph University, Beirut
Research
Publications
-
MET alterations in advanced non-small cell lung cancer.
Curr Probl Cancer Volume: 49 Page(s): 101075
04/01/2024 Authors: Chagas GCL; Rangel AR; El Osta B -
A Phase 1/2 Study to Evaluate the Safety and Activity of Nivolumab in Combination With Vorolanib, a Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitor, in Patients With Refractory Thoracic Tumors.
JTO Clin Res Rep Volume: 5 Page(s): 100619
02/01/2024 Authors: Beckermann KE; Bestvina CM; El Osta B; Sanborn RE; Borghaei H; Lammers PE; Selvaggi G; Whisenant JG; Heimann-Nichols E; Berry L -
Is It Prime Time for Perioperative Therapy in Patients With Resectable Non-Small-Cell Lung Cancer?
JCO Oncol Pract Volume: 19 Page(s): 685 - 687
09/01/2023 Authors: El Osta B; Ababneh O -
KRAS G12C mutation: from undruggable target to potentially agnostic biomarker.
Transl Lung Cancer Res Volume: 12 Page(s): 1147 - 1151
06/30/2023 Authors: El Osta B -
A Phase 2 Study of Docetaxel, Ramucirumab, and Pembrolizumab for Patients With Metastatic or Recurrent Non-Small-Cell Lung Cancer (NSCLC) who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade.
Clin Lung Cancer Volume: 23 Page(s): e400 - e404
11/01/2022 Authors: Osta BE; Carlisle J; Steuer C; Pakkala S; Leal T; Dhodapkar M; Liu Y; Chen Z; Owonikoko T; Ramalingam S -
Novel targeted therapies for advanced non-small lung cancer.
Semin Oncol Volume: 49 Page(s): 326 - 336
06/01/2022 Authors: Abughanimeh O; Kaur A; El Osta B; Ganti AK -
RET Fusion: Joining the Ranks of Targetable Molecular Drivers in NSCLC.
JTO Clin Res Rep Volume: 1 Page(s): 100050
09/01/2020 Authors: Osta BE; Ramalingam SS -
Characteristics and Outcomes of Patients With Metastatic KRAS-Mutant Lung Adenocarcinomas: The Lung Cancer Mutation Consortium Experience.
J Thorac Oncol Volume: 14 Page(s): 876 - 889
05/01/2019 Authors: El Osta B; Behera M; Kim S; Berry LD; Sica G; Pillai RN; Owonikoko TK; Kris MG; Johnson BE; Kwiatkowski DJ -
First Report of Parkinsonism Associated With Indoximod, an Immune-Modulating Agent.
J Glob Oncol Volume: 4 Page(s): 1 - 2
09/01/2018 Authors: Floyd M; El Osta B; Tang S-C -
Not all immune-checkpoint inhibitors are created equal: Meta-analysis and systematic review of immune-related adverse events in cancer trials.
Crit Rev Oncol Hematol Volume: 119 Page(s): 1 - 12
11/01/2017 Authors: El Osta B; Hu F; Sadek R; Chintalapally R; Tang S-C